AU2003219955A1 - Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists - Google Patents

Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists

Info

Publication number
AU2003219955A1
AU2003219955A1 AU2003219955A AU2003219955A AU2003219955A1 AU 2003219955 A1 AU2003219955 A1 AU 2003219955A1 AU 2003219955 A AU2003219955 A AU 2003219955A AU 2003219955 A AU2003219955 A AU 2003219955A AU 2003219955 A1 AU2003219955 A1 AU 2003219955A1
Authority
AU
Australia
Prior art keywords
isoquinoline
receptor antagonists
amino acid
excitatory amino
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219955A
Inventor
Miriam Filadelfa Del Prado
Esteban Dominguez-Manzanares
Sandra Ann Filla
Kevin John Hudziak
Ana Isabel Mateo Herranz
Paul Leslie Ornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2003219955A1 publication Critical patent/AU2003219955A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003219955A 2002-03-22 2003-03-12 Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists Abandoned AU2003219955A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES02380067.5 2002-03-22
ES200203867 2002-03-22
US44134503P 2003-01-17 2003-01-17
US60/441,345 2003-01-17
PCT/US2003/006156 WO2003082856A1 (en) 2002-03-22 2003-03-12 Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
AU2003219955A1 true AU2003219955A1 (en) 2003-10-13

Family

ID=28676454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219955A Abandoned AU2003219955A1 (en) 2002-03-22 2003-03-12 Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists

Country Status (2)

Country Link
AU (1) AU2003219955A1 (en)
WO (1) WO2003082856A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511741B1 (en) 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
TWI593692B (en) * 2013-03-12 2017-08-01 美國禮來大藥廠 Tetrahydropyrrolothiazine compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists

Also Published As

Publication number Publication date
WO2003082856A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
IL174299A0 (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
AU2003299807A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2003245700A1 (en) Pyrazolopyridine derivatives
AU2003261392A1 (en) M3muscarinic acetylcholine receptor antagonists
AU2003231513A1 (en) Pgd2 receptor antagonist
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
AU2005234596A8 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
AU2003273989A1 (en) Quinazolinone derivatives useful as anti-hyperalgesic agents
AU2003275838A1 (en) Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2002953255A0 (en) Protein kinase inhibitors
AU1433901A (en) Excitatory amino acid derivatives
AU2003299600A1 (en) The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2003280838A1 (en) Indole derivatives as somatostatin agonists or antagonists
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
EP1552826A4 (en) Amino acid compositions for improving central functions
AU2003300904A1 (en) Antagonists for human prolactin
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
AUPS251502A0 (en) Protein kinase inhibitors
AU2003219955A1 (en) Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
AU2003210778A1 (en) Amino acid transporters
AU2002227020A1 (en) Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
AU2003255954A1 (en) Substituted glycine derivatives for use as medicaments
AU2003255803A1 (en) Quinazolinone derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase